Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Study identifier:MB102-074
ClinicalTrials.gov identifier:NCT01068756
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Dapagliflozin, Rifampin
Sex
All
Actual Enrollment
14
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Mar 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Bristol-Myers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: Dapagliflozin/Rifampin | Drug: Dapagliflozin Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days Drug: Rifampin Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days |
Contacts
Contact
AstraZeneca Clinical Study Information Center Study Information Center
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
